Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering

January 30, 2017 updated by: University of Oxford
This study aims to test whether the addition of transcranial direct current stimulation (TDCS) to speech fluency training results in improvements in speech fluency in adults with developmental stuttering. Half of the participants will receive anodal TDCS on five consecutive days, the other half will receive a sham stimulation for the same amount of time.

Study Overview

Detailed Description

Studies using TDCS have shown improvements in motor performance, and in expressive language skills in clinical and healthy populations. The benefits of single sessions of TDCS are short-lived. However, stimulation over multiple sessions can increase and prolong learning effects that can persist for several weeks after the end of the stimulation period. We aim to target left hemisphere frontal regions involved in speech production with TDCS, and to pair this stimulation with speech fluency training.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Native speaker of English.
  • Right handed.
  • Participant has moderate to severe Developmental Stuttering (Stammering)

Exclusion Criteria:

  • Speech, language or communication disorder other than Developmental Stuttering.
  • Sensory impairment (hearing loss or visual impairment)
  • History of drug abuse.
  • History of seizures
  • History of a neurological or psychiatric illness.
  • History of neurosurgical procedure.
  • Currently taking certain prescription medications such as anti-depressants and anti-malarial medication (as these may lower the seizure threshold)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anodal TDCS
Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
Sham Comparator: Sham TDCS
Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline proportion of stuttering in speech sample
Time Frame: 1 week post-treatment
Quantitative measurement of stuttering
1 week post-treatment
Change from baseline proportion of stuttering in speech sample
Time Frame: 6 weeks post-treatment
Quantitative measurement of stuttering
6 weeks post-treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline on the Stuttering Severity Instrument version 4 (SSI-4)
Time Frame: 1 week post-treatment
Standardised assessment of frequency and duration of stuttering and associated physical concomitants
1 week post-treatment
Change from baseline on the Stuttering Severity Instrument version 4 (SSI-4)
Time Frame: 6 weeks post-treatment
Standardised assessment of frequency and duration of stuttering and associated physical concomitants
6 weeks post-treatment
Change from baseline on Overall Assessment of Speaker's Experience of Stuttering (OASES)
Time Frame: 6 weeks post-treatment
Standardised assessment of the functional impact of stuttering on a person's life
6 weeks post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kate Watkins, PhD, University of Oxford

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2014

Primary Completion (Actual)

March 14, 2016

Study Completion (Actual)

March 14, 2016

Study Registration Dates

First Submitted

September 30, 2014

First Submitted That Met QC Criteria

November 6, 2014

First Posted (Estimate)

November 11, 2014

Study Record Updates

Last Update Posted (Estimate)

January 31, 2017

Last Update Submitted That Met QC Criteria

January 30, 2017

Last Verified

January 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Speech Disorders

Clinical Trials on Anodal TDCS

Subscribe